Aphria (NASDAQ:APHA) announced its quarterly earnings results on Wednesday. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.39), Briefing.com reports. Aphria had a negative return on equity of 2.23% and a negative net margin of 18.30%. The company had revenue of $160.50 million during the quarter, compared to analysts’ expectations of $153.75 million. During the same period last year, the firm earned ($0.03) earnings per share. Aphria’s revenue for the quarter was up 33.1% on a year-over-year basis.
Shares of Aphria stock opened at $12.42 on Friday. Aphria has a 12-month low of $1.95 and a 12-month high of $14.01. The company has a quick ratio of 3.30, a current ratio of 5.37 and a debt-to-equity ratio of 0.22. The company has a 50-day moving average of $7.62 and a two-hundred day moving average of $6.45.
Several equities research analysts have commented on the company. Stifel Nicolaus downgraded Aphria from a “buy” rating to a “hold” rating in a report on Thursday, December 17th. Alliance Global Partners upped their price objective on Aphria from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. CIBC upped their price objective on Aphria from $12.50 to $18.00 and gave the company an “outperform” rating in a research report on Friday. BMO Capital Markets upped their price target on Aphria from $7.00 to $15.00 and gave the stock a “market perform” rating in a research report on Friday. Finally, Cantor Fitzgerald increased their price target on Aphria from $11.75 to $26.00 and gave the company an “overweight” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $14.23.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.